Prof. Vasco Bonifácio (DBE, iBB), and collaborators from CEFEMA (IST), the Faculty of Veterinary Medicine – University of Lisbon, the Instituto de Higiene e Medicina Tropical (IHMT) and ITQB – NOVA University of Lisbon, and the Faculty of Sciences – University of Lisbon, reported in Antibiotics a novel therapeutic strategy to treat diabetic foot infections (DFIs).  DFIs pose a significant clinical burden, often leading to repeated hospitalizations, amputations, and high mortality rates due to resistant polymicrobial biofilms. In this study three non-resistance-promoting therapeutic candidates were evaluated (in vitro and in vivo – Galleria mellonella model) against Staphylococcus aureus and Pseudomonas aeruginosa isolates from DFIs: the antimicrobial peptide Nisin Z, the polycationic pharmadendrimer PURE_G4OEI₄₈ (patented by Prof. Vasco Bonifácio) and amlodipine. These findings position Nisin Z and PURE_G4OEI₄₈ as promising topical adjuncts for mild DFIs, combining selective action without driving resistance. Further evaluation in more complex models is critical to confirm safety and clinical viability. See more.